Johnson & Johnson’s strategic shift to higher growth medical device markets like cardiovascular is paying off, as the business was the only medtech unit to grow by double digits in the first quarter.
J&J’s cardiovascular unit stands out again in Q1
Johnson & Johnson’s strategic shift to higher growth medical device markets like cardiovascular is paying off, as the business was the only medtech unit to grow by double digits in the first quarter.